How can polygenic inheritance be used in population screening for common diseases?

Genetics in Medicine

Volumn 15, Issue 6, 2013, Pages 437-443

  Khoury, Muin J ^a,b   Janssens, A Cecile J W ^c   Ransohoff, David F ^d,e  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e IL   (United States)

Author keywords

evidence based medicine; genetics; genomics; polygenic model; public health; risk assessment; screening

Indexed keywords

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER SCREENING; CLINICAL PRACTICE; COLORECTAL CANCER; GENETIC RISK; GENETIC SCREENING; GENOMICS; HEALTH CARE COST; HEALTH CARE SYSTEM; HEREDITY; HUMAN; MAMMOGRAPHY; MASS SCREENING; MORBIDITY; OUTCOME ASSESSMENT; PROSTATE CANCER; RISK ASSESSMENT; RISK FACTOR;

EVIDENCE-BASED MEDICINE; FEMALE; GENETIC TESTING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MASS SCREENING; MULTIFACTORIAL INHERITANCE; NEOPLASMS;

EID: 84878841277     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.182     Document Type: Article

References (59)

1. Chowdhury S, Dent T, Pashayan N, et al. Incorporating genomics in breast and prostate cancer screening: assessing the implications. Genet Med 2013, e-pub ahead of print February 14.
2. Harris R, Sawaya GF, Moyer VA, Calonge N. Reconsidering the criteria for evaluating proposed screening programs: reflections from 4 current and former members of the U.S. Preventive Services Task Force. Epidemiol Rev 2011;33: 20-35.
3. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. World Health Organization: Geneva, Switzerland, 1968.
4. Harris R. Overview of screening: where we are and where we may be headed. Epidemiol Rev 2011;33:1-6.
5. United States Prevent ive Services Task Force. http://www. uspreventiveservicestaskforce.org/index.html Accessed 18 November 2012.
6. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 2011;8:184-187.
7. US Preventive Services Task Force. Screening for breast cancer: USPSTF recommendation statement. Ann Int Med 2010;151:716-726.
8. American College of Radiology: detailed ACR statement on ill advised and dangerous USPSTF mammography recommendations. http://gm.acr.org/ MainMenuCategories/media-room/FeaturedCategories/PressReleases/UPSTFDetails. aspx Accessed 26 July 2012.
9. Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120-134.
10. Hindorff LA, Gillanders EM, Manolio TA. Genetic architecture of cancer and other complex diseases: lessons learned and future directions. Carcinogenesis 2011;32:945-954.
11. National Center for Biotechnology Information: Genetic Testing Registry. http://www.ncbi.nlm.nih.gov/gtr/Accessed 26 July 2012.
12. Bick D, Dimmock D. Whole exome and whole genome sequencing. Curr Opin Pediatr 2011;23:594-600.
13. Manolio TA, Green ED. Genomics reaches the clinic: from basic discoveries to clinical impact. Cell 2011;147:14-16.
14. National Newborn Screening and Genetics Resource Center. http://genes-r-us. uthscsa.edu/Accessed 19 November 2012.
15. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics 2006;117:1915-1921. (Pubitemid 46071234)
16. US Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Int Med 2005;143:355-361.
17. U S Preventive Services Task Force. Screening for colorectal cancer: recommendation statement. Ann Int Med 2008;149:627-637.
18. Vasen HF, Möslein G, Alonso A, et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007;44:353-362. (Pubitemid 46953715)
19. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) working group. Recommendation from the EGAPP working group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med 2009;11:35-41.
20. Lange K. An approximate model of polygenic inheritance. Genetics 1997;147:1423-1430. (Pubitemid 27467480)
21. Visscher PM, Hill WG, Wray NR. Heritability in the genomics era-concepts and misconceptions. Nat Rev Genet 2008;9:255-266.
22. Yu W, Yesupriya A, Wulf A, et al. GWAS Integrator: a bioinformatics tool to explore human genetic associations reported in published genome-wide association studies. Eur J Hum Genet 2011;19:1095-1099.
23. Willems SM, Mihaescu R, Sijbrands EJ, van Duijn CM, Janssens AC. A methodological perspective on genetic risk prediction studies in type 2 diabetes: recommendations for future research. Curr Diab Rep 2011;11:511-518.
24. Mihaescu R, Meigs J, Sijbrands E, et al. Genetic risk profiling for prediction of type 2 diabetes. PLoS Curr 2011;11:3RRN1208.
25. Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med 2008;358:1240-1249. (Pubitemid 351439225)
26. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008;100:1037-1041. (Pubitemid 352019794)
27. Wacholder S, Hartge P, Prentice R, et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010;362:986-993.
28. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008;358:910-919. (Pubitemid 351397090)
29. Salinas CA, Koopmeiners JS, Kwon EM, et al. Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate 2009;69:363-372.
30. Jafari N, Broer L, van Duijn CM, Janssens AC, Hintzen RQ. Perspectives on the use of multiple sclerosis risk genes for prediction. PLoS ONE 2011;6:e26493.
31. Pashayan N, Pharoah P. Translating genomics into improved population screening: hype or hope? Hum Genet 2011;130:19-21.
32. Doerr M, Teng K. Family history: still relevant in the genomics era. Cleve Clin J Med 2012;79:331-336.
33. Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature 2009;461:747-753.
34. Wald NJ, Morris JK. Personalized medicine: hope or hype. Eur Heart J 2012;33:1553-1554.
35. Bleyer A, Welch HG. Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med 2012;367:1998-2005.
36. Kmietowicz Z. Adding age and genetic risk to PSA test could improve screening for prostate cancer. BMJ 2012;345:e7467.
37. Howard K, Barratt A, Mann GJ, Patel MI. A model of prostate-specific antigen screening outcomes for low-to high-risk men: information to support informed choices. Arch Intern Med 2009;169:1603-1610.
38. Agency for Healthcare Research Quality, technical report: multigene panels in prostate cancer risk assessment. http://effectivehealthcare.ahrq.gov/ index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct& product id=1172 Accessed 19 November 2012.
39. NIH consensus development program. Enhancing the use and quality of colorectal cancer screening: final panel statement 2009. http://consensus.nih. gov/2010/colorectalstatement.htm Accessed 26 July 2012.
40. Hawken SJ, Greenwood CM, Hudson TJ, et al. The utility and predictive value of combinations of low penetrance genes for screening and risk prediction of colorectal cancer. Hum Genet 2010;128:89-101.
41. Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006;42:216-227. (Pubitemid 43083493)
42. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994;331:1669-1674. (Pubitemid 24373618)
43. Wilschut JA, Steyerberg EW, van Leerdam ME, Lansdorp-Vogelaar I, Habbema JD, van Ballegooijen M. How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer? Cancer 2011;117:4166-4174.
44. Ku CS, Wu M, Cooper DN, et al. Technological advances in DNA sequence enrichment and sequencing for germline genetic diagnosis. Expert Rev Mol Diagn 2012;12:159-173.
45. Khoury MJ, Gwinn M, Clyne M, Yu W. Genetic epidemiology with a capital E, ten years after. Genet Epidemiol 2011;35:845-852.
46. Manolio TA, Bailey-Wilson JE, Collins FS. Genes, environment and the value of prospective cohort studies. Nat Rev Genet 2006;7:812-820. (Pubitemid 44413225)
47. Manolio TA, Weis BK, Cowie CC, et al. New models for large prospective studies: is there a better way? Am J Epidemiol 2012;175:859-866.
48. Salari K, Watkins H, Ashley EA. Personalized medicine: hope or hype? Eur Heart J 2012;33:1564-1570.
49. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer 2012;118:5955-5963.
50. Ransohoff DF, Pignone M, Russell LB. Using models to make policy: an inflection point? Med Decis Making 2011;31:527-529.
51. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP working group. Genet Med 2009;11:3-14.
52. Goddard KA, Knaus WA, Whitlock E, et al. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med 2012;14:633-642.
53. Veenstra DL, Roth JA, Garrison LP Jr, Ramsey SD, Burke W. A formal riskbenefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med 2010;12:686-693.
54. Burke W, Tarini B, Press NA, Evans JP. Genetic screening. Epidemiol Rev 2011;33:148-164.
55. Evans JP, Burke W, Khoury M. The rules remain the same for genomic medicine: the case against "reverse genetic exceptionalism." Genet Med 2010;12:342-343.
56. Grosse SD, McBride CM, Evans JP, Khoury MJ. Personal utility and genomic information: look before you leap. Genet Med 2009;11:575-576.
57. Myers MF, Bernhardt BA. Direct-to-consumer genetic testing: introduction to the special issue. J Genet Couns 2012;21:357-360.
58. Spencer DH, Lockwood C, Topol E, et al. Direct-to-consumer genetic testing: reliable or risky? Clin Chem 2011;57:1641-1644.
59. Khoury MJ, McBride CM, Schully SD, et al. The Scientific Foundation for Personal Genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med 2009;11:559-567.